Editorial Board — Medscape Oncology
Board Members
- Harold J. Burstein, MD, PhD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- David J. Kerr, MD
- University of Oxford
Oxford Cancer Centre
Oxford, United Kingdom
- University of Oxford
- Mark G. Kris, MD
- Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College
New York, New York
- Memorial Sloan-Kettering Cancer Center
- Corey J. Langer, MD
- University of Pennsylvania Medical School
Abramson Cancer Center
Philadelphia, Pennsylvania
- University of Pennsylvania Medical School
- Maurie Markman, MD
- Drexel University College of Medicine
Cancer Treatment Centers of America
Philadelphia, Pennsylvania
- Drexel University College of Medicine
- John L. Marshall, MD
- Georgetown University
Washington, DC
- Georgetown University
- Kathy D. Miller, MD
- Indiana University School of Medicine
Indiana University Simon Cancer Center
Indianapolis, Indiana
- Indiana University School of Medicine
- Richard M. Stone, MD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Nicholas J. Vogelzang, MD
- University of Nevada School of Medicine
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
- University of Nevada School of Medicine
- Louis M. Weiner, MD
- Georgetown University Medical Center
Lombardi Comprehensive Cancer Center
Washington, DC
- Georgetown University Medical Center
- John R. Wingard, MD
- University of Florida
Shands Cancer Hospital at the University of Florida
Gainesville, Florida
- University of Florida
Board Member Details
Harold J. Burstein, MD, PhD
![Harold J. Burstein, MD, PhD](http://img.medscape.com/pi/global/hs/hs-burstein.harold.gif)
Professor, Department of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
David Kerr, MD, DSc
![David J. Kerr, MD](http://img.medscape.com/person/kerr_david.png)
Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom
David Kerr, MD, DSc, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVE; ASCO
Have a 5% or greater equity interest in: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVEA; ASCO
Received income in an amount equal to or greater than $250 from: Celleron Therapeutics; Oxford Cancer Biomarkers; IQVEA; ASCO
Mark G. Kris, MD
![Mark G. Kris, MD](http://img.medscape.com/person/kris_mark_2.jpg)
Professor, Department of Medicine, Weill Cornell Medical College; Attending Physician, Memorial Sloan Kettering Cancer Center, New York, NY
Mark G. Kris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Daiichi Sankyo Company, Limited; Pfizer Inc.
Meals and travel provided by: Genentech, Inc.
Corey J. Langer, MD
![Corey J. Langer, MD](http://img.medscape.com/pi/global/hs/hs-langer.corey.gif)
Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania
Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Pfizer; Eli Lilly; Genentech; OSI (Astellas); Merck; GlaxoSmithKline; Nektar; Advantage; Clovis; Inovio; Ariad; StemCentrx; Takeda
Served as a scientific advisor for: AbbVie; Bristol Myers Squibb; ImClone; Pfizer; Eli Lilly; AstraZeneca; Novartis; Roche/Genentech; Bayer/Onyx; Abbott; Morphotek; Biodesix; Clarient; Caris Dx; Vertex; Synta; Celgene; Boehringer-Ingelheim; Hospira; Helsinn; Clovis; Ariad (Takeda); Takai; Regeneron
Data Safety Monitoring Committee Member: Eli Lilly; Amgen; Synta; Agennix; SWOG; Peregrine; Incyte
CME: Projects in Knowledge; Physicians' Education Resource; Network of Oncology Clinicians and Researchers; Imedex; Clinical Care Options; Research to Practice; Med Learning Group; TRM Oncology; WebMD
Maurie Markman, MD
![Maurie Markman, MD](http://img.medscape.com/pi/global/hs/hs-markman-maurie.jpg)
Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania
Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
John L. Marshall, MD
![John L. Marshall, MD](http://img.medscape.com/person/marshall_john.jpg)
Professor, Chief, Division of Hematology-Oncology, Department of Oncology, Georgetown University; Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Hospital, Washington, DC
John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiko Pharmaceutical Co., Ltd.; Merck & Co., Inc.; Individ-med; Caris Life Sciences, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiko Pharmaceutical Co., Ltd.; Merck & Co., Inc.
Kathy D. Miller, MD
![Kathy D. Miller, MD](http://img.medscape.com/person/miller.kathy.jpg)
Professor, Department of Hematology/Oncology; Associate Director, Indiana University School of Medicine, Indianapolis, Indiana
Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck & Co.
Richard M. Stone, MD
![Richard M. Stone, MD](http://img.medscape.com/pi/global/hs/hs-stone-richard.jpg)
Professor of Medicine, Harvard Medical School; Director, Translational Research Division, Dana-Farber Cancer Institute, Boston, Massachusetts
Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie; Actinium; Agios; Amgen Inc.; Arog; Astellas; AstraZeneca; Celgene; Cornerstone; Jazz; Macrogenics; Novartis; Otsuka/Astex; Pfizer; Stemline
Received research funding from: Agios; Arog; Novartis
Serve(d) on the Data Safety and Monitoring Board for: Celgene; Argenx; Takeda
Serve(d) on the Steering Committee for: Celgene
Nicholas J. Vogelzang, MD
![Nicholas J. Vogelzang, MD](http://img.medscape.com/pi/global/hs/hs-vogelzang.n.gif)
Professor of Clinical Medicine, University of Nevada School of Medicine, University of Nevada, Las Vegas, Nevada
Serve(d) as a consultant, advisor, or a member of a Scientific Advisory Board for: Astellas; AstraZeneca; Cancer Exper Now; Carls; Clovis; Corvus; Eisai; Exelexis; GeneCentric; Genentech; Janssen; Merck
Serve(d) as a speaker or a member of a speakers bureau for: Bayer; Carls; Clovis
Clinical/phase 1/post-registration trial with: Aravive; Arrowhead; Arvinas; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera; Clovis; Corvus; Dendreon; eFFECTOR; Eisai; Endocyte; Epizyme; ESSA; Exelexis; Genentech; Immunomedics; Kangpu; Kintor Suzhou; Macrogenics; Merck; Mirati; Modra
Project with US Oncology of Real World outcomes in metastatic prostate cancer: Amgen
Louis M. Weiner, MD
![Louis M. Weiner, MD](http://img.medscape.com/pi/global/hs/hs-weiner-louis.jpg)
Chairman, Francis L. and Charlotte G. Gragnani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center; Director, MedStar Georgetown Cancer Institute, Georgetown University Medical Center, Washington, DC
Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Scientific Advisory Board for: Celldex; Jounce Therapeutics; Immunome; Klus Pharmaceuticals; Forty-Seven, Inc.
Serve(d) on the External Advisory Board for: Cytomx
Serve(d) on the Clinical Advisory Board for: Bioxcel
Serve(d) as a consultant for: Novartis
Is the co-founder of: Jounce Therapeutics
Has investment in: Targeted Diagnostic and Therapeutics, Inc.
John R. Wingard, MD
![John R. Wingard, MD](http://img.medscape.com/person/wingard.john.jpg)
Professor, Department of Medicine, University of Florida College of Medicine; Director, Bone Marrow Transplant Program, Shands Hospital at University of Florida, Gainesville, Florida
John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Shire; Celgene; Ansun BioPharma; Merck; ReViral; AlloVir; Astellas Pharma; Pluristem Therapeutics; Cidara Therapeutics
Serve(d) as a speaker or a member of a spekers bureau for: United Medical (Brazil)
Received research grant from: National Institutes of Health